These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24467965)

  • 1. Mevalonate metabolism in cancer.
    Gruenbacher G; Thurnher M
    Cancer Lett; 2015 Jan; 356(2 Pt A):192-6. PubMed ID: 24467965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell metabolism: cancer's Achilles' heel.
    Kroemer G; Pouyssegur J
    Cancer Cell; 2008 Jun; 13(6):472-82. PubMed ID: 18538731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mevalonate Pathway Provides Ubiquinone to Maintain Pyrimidine Synthesis and Survival in p53-Deficient Cancer Cells Exposed to Metabolic Stress.
    Kaymak I; Maier CR; Schmitz W; Campbell AD; Dankworth B; Ade CP; Walz S; Paauwe M; Kalogirou C; Marouf H; Rosenfeldt MT; Gay DM; McGregor GH; Sansom OJ; Schulze A
    Cancer Res; 2020 Jan; 80(2):189-203. PubMed ID: 31744820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of mevalonate metabolism in cancer and immune cells.
    Thurnher M; Gruenbacher G; Nussbaumer O
    Biochim Biophys Acta; 2013 Jun; 1831(6):1009-15. PubMed ID: 23524243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T lymphocyte regulation by mevalonate metabolism.
    Thurnher M; Gruenbacher G
    Sci Signal; 2015 Mar; 8(370):re4. PubMed ID: 25829448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.
    Palozza P; Colangelo M; Simone R; Catalano A; Boninsegna A; Lanza P; Monego G; Ranelletti FO
    Carcinogenesis; 2010 Oct; 31(10):1813-21. PubMed ID: 20699249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting mutant p53 through the mevalonate pathway.
    Freed-Pastor W; Prives C
    Nat Cell Biol; 2016 Oct; 18(11):1122-1124. PubMed ID: 27784901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms.
    Liu Y; Zhang W; Cao Y; Liu Y; Bergmeier S; Chen X
    Cancer Lett; 2010 Dec; 298(2):176-85. PubMed ID: 20678861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism.
    Keijer J; Bekkenkamp-Grovenstein M; Venema D; Dommels YE
    Biochim Biophys Acta; 2011 Jun; 1807(6):697-706. PubMed ID: 20732296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell immunometabolism against cancer.
    Jiang S; Yan W
    Cancer Lett; 2016 Nov; 382(2):255-258. PubMed ID: 27664755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel aspects of mevalonate pathway inhibitors as antitumor agents.
    Thurnher M; Nussbaumer O; Gruenbacher G
    Clin Cancer Res; 2012 Jul; 18(13):3524-31. PubMed ID: 22529099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular biological characteristics of cancer].
    Kushlinskiĭ NE; Nemtsova MV
    Vestn Ross Akad Med Nauk; 2014; (1-2):5-15. PubMed ID: 25055553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes.
    Allison KE; Coomber BL; Bridle BW
    Immunology; 2017 Oct; 152(2):175-184. PubMed ID: 28621843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models.
    Gatenby RA; Gawlinski ET
    Cancer Res; 2003 Jul; 63(14):3847-54. PubMed ID: 12873971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis.
    Daye D; Wellen KE
    Semin Cell Dev Biol; 2012 Jun; 23(4):362-9. PubMed ID: 22349059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose avidity of carcinomas.
    Ortega AD; Sánchez-Aragó M; Giner-Sánchez D; Sánchez-Cenizo L; Willers I; Cuezva JM
    Cancer Lett; 2009 Apr; 276(2):125-35. PubMed ID: 18790562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNAs link metabolic reprogramming to oncogenesis.
    Hatziapostolou M; Polytarchou C; Iliopoulos D
    Trends Endocrinol Metab; 2013 Jul; 24(7):361-73. PubMed ID: 23602813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
    Ganapathy-Kanniappan S
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 as a Regulator of Lipid Metabolism in Cancer.
    Parrales A; Iwakuma T
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Regulation of Apoptosis in Cancer.
    Matsuura K; Canfield K; Feng W; Kurokawa M
    Int Rev Cell Mol Biol; 2016; 327():43-87. PubMed ID: 27692180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.